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Abstract: Postpartum depression (PPD) is one of themost
frequent complications of childbirth affecting ~500,000
women annually (prevalence 10% to 15%). Despite the
documented adverse outcomes for mother and child, there
remains a great need to develop prospective approaches to
identify women at risk. This review examines some of the
best-characterized molecular and clinical risk factors for
PPD.We illustrate that this is a growing literature but there
remains a lack of reliable molecular predictors for PPD.
Current best predictors are clinical assessments for psychi-
atric history and adverse life events, highlighting the need
for increased depression screening across the perinatal
period.
Key words: postpartum depression, predictors, molec-
ular, biomarker, risk assessment
Introduction and Background
Postpartum depression (PPD) is a perinatal
form of major depressive disorder (MDD)
and affects ~500,000 women annually in the
United States (prevalence 10% to 15%).1
PPD is one of the most frequent complica-
tions of childbirth2 and is associated with
many adverse outcomes for bothmother and
offspring including, maternal mortality and
morbidity,1 increased risk for infanticide,3
poorer maternal-infant attachment, and im-
paired parenting behaviors.2 There is a great
need for prospective approaches that identify
women at risk for PPD. This is a growing
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individual to any given disorder. The herit-
ability of PPD is ~50%4 which means that
half of the phenotypic variation seen in PPD
is due to genetic variation. This is higher than
the heritability of MDD (32%) suggesting
that PPD may be a more homogenous
subtype of depression. These recent heritabil-
ity findings represent a leap in our under-
standing of the genetics of PPD. However,
our ability to use patient DNA sequences to
estimate individual risk for PPD is not
currently feasible. Much of the published
research into the genetic associations with
PPD focuses on candidate genes. Although
the evidence may appear convincing for any
one study, candidate genes overall have
shown they are not a reliable mechanism to
predict PPD risk. First, candidate gene
studies often rely on small sample sizes and
are not able to be replicated. Second,
they often do not account for population
differences in genetic variation. Using the
commonly studied BDNF Val66Met poly-
morphism as an example, those of European
ancestry are homozygous for the G allele
60% of the time. This is compared with those
of African ancestry who are homozygous for
the G allele >80% of the time. These drastic
changesmay appear as significant differences
between PPD cases and controls when they
are actually just measures of population
structure. Candidate gene studies are typi-
cally not able to account for these changes in
genetic ancestry. There has been a single
study that looks at the effect of genetic
ancestry on predictors of PPD.5 They
showed that genetic ancestry was not a
predictor of PPD and did not modify the
predictive value of other risk factors. Lastly,
candidate gene studies, by definition, do not
take into account the variation of individuals
across the genome. No single gene or variant
works alone in terms of biological function.
These reasons are perhaps why no candidate
gene has been shown to explain the variation
associated with PPD or any other psychiatric
disorder. Current genomics approaches, such
as genetic risk score prediction, use variation
across the genome to provide risk estimates
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Evidence level indicates if there are positive associations with 
PPD, mixed associations, or null findings (no associations).
PPD indicates postpartum depression.
field of research that seeks to predict those 
women at risk for PPD so that prevention 
and early detection are possible.
The purpose of this review is to examine 
some of the best-characterized molecular 
and clinical risk factors for PPD (Table 1). 
These risk factors are divided into 2 catego-
ries: inherent or prepregnancy risk factors 
and perinatal risk factors. It is important to 
recognize that there is no single predictor of 
PPD that currently exists. What we present 
here are the risk factors that represent the 
largest increases in the odds for developing 
PPD, measured using prospective studies.
Inherent or Prepregnancy Risk
Factors
In this section, we highlight an individual’s 
putative risk factors that exist before preg-
nancy. These areas of risk are important to 
note because they can significantly contrib-
ute to an individual’s risk and may not be 
assessed during routine screening for PPD.
GENETICS
DNA provides every individual with a base-
line risk of disease. It is the unique combina-
tion of all genetic variants that predisposes an
for various psychiatric disorders. However,
genetic risk scores for PPD have not yet been
established and are an area of current
research. This method has allowed for initial
investigations into the genetic overlap be-
tween PPD and other mood disorders.6
Ultimately, the goal of genetic risk scores is
to provide a clinical risk assessment for PPD
based on an individual’s unique genetic
background. However, this goal is not im-
mediately feasible and is reliant on very large
sample sizes.
EPIGENETICS
Epigenetics refers to changes in gene func-
tion that do not alter the DNA sequence
itself. The PPD literature focuses mainly on
DNA methylation, which is the addition of
methyl groups to the DNA that regulate
gene transcription and cell specificity. This
type of epigenetic modification is of partic-
ular interest in psychiatry because DNA
methylation is altered by stress, medication,
and reproductive hormones. The identifica-
tion of DNA methylation biomarkers has
been particularly successful in PPD. Using
blood drawn at any point during pregnancy,
DNA methylation at 2 genomic locations,
along with complete blood count data, was
able to prospectively predict PPD case status
(determined using clinician diagnosis) with
96% accuracy (area under the receiver oper-
ating characteristic curve, AUC=0.96).7
This prediction is irrespective of maternal
antenatal depression status. These bio-
markers were first identified in a relatively
small sample of women (n=52), but have
been since replicated in 2 additional cohorts
with 81% accuracy (AUC=0.81).8 In addi-
tion, DNA methylation at the oxytocin
receptor gene (OXTR) was found to reflect
changes in inflammatory cell types and can
be used as a proxy for complete blood count
data in the PPD prediction model.9 These
epigenetic biomarkers are promising and
would require a more large-scale clinical
trial before implementation in the clinic.
Although the literature on PPD-related epi-
genetics is currently small, it shows promise
as a way to develop a clinically meaningful
biomarker.
NEUROACTIVE MOLECULES
Much of the biological literature associated
with PPD focuses on the association with
neuroactivemolecules, such as hormones and
neuropeptides. The recent literature shows a
focus on reproductive hormones, BDNF,10
γ-aminobutyric acid,11 and ghrelin.12 When
examining these studies through the lens of
predicting PPD, it is important to note that
these are reporting on cross-sectional associ-
ations and should not be interpreted as
predictive without more longitudinal follow-
up. However, there are several longitudinal
studies examining the predictive ability of
neuroactive molecules that we discuss next.
Allopregnanolone
A metabolite of progesterone, allopregna-
nolone is a positive allosteric modulator of
the γ-aminobutyric acid-A receptor. Recent
work has shown positive treatment effects in
clinical trials as a novel treatment for PPD
using a proprietary intravenous formulation
of allopregnanolone, brexanolone.13 How-
ever, its potential as a predictor of PPD
onset has not been completely evaluated. A
single exploratory study has been published
looking at plasma allopregnanalone in the
second and third trimesters as a predictor of
PPD.14 Their relatively small sample size of
60 women found that lower second trimes-
ter allopregnanalone increased the odds of
developing subsequent PPD. More work
will need to be conducted to replicate and
refine the predictive ability of antepartum
allopregnanalone, but this work is encour-
aging and aligns with the recent therapeutic
findings.
β-endorphin
β-endorphin is an endogenous opioid neuro-
peptide created by the metabolism of proo-
piomelanocortin (POMC). It has associated
function within the hypothalamic-pituitary-
adrenal axis (HPA) making it an attractive
candidate for association with PPD. In a
pregnancy, the placenta produces CRH,
which is followed by an abrupt drop
postdelivery mirroring the milieu of repro-
ductive hormones. Unlike reproductive
hormone levels which have been shown
not to be predictive of PPD, CRH has
shown positive results. Work by Yim
et al19 and Iliadis et al20 independently
used longitudinal studies during pregnancy
and into the postpartum period. Yim and
colleagues used week 25 CRH to predict
PPD at 4-week postpartum using an
EPDS threshold of ≥ 10 to define PPD
case status. Using a similar experimental
model, Iliadis and colleagues used week 17
CRH to predict PPD at 6-week postpar-
tum defining PPD cases with a more
stringent EPDS threshold of ≥ 13.
Although these findings are similar and
point to the same outcome of CRH pre-
diction of PPD, the differences may be
driven by small differences in study design,
most notably follow-up period and EPDS
thresholds for PPD case status. A follow-
up study, or possibly a reanalysis, could
harmonize these results. However, another
large study found no association between
pregnancy levels of CRH and subsequent
PPD onset.21 This may also be an artifact
of differences in study design with the null
findings using less specific windows for
sampling during pregnancy (< 20 wk and
24 to 29wk), EPDS thresholds (≥ 12), and
PPD follow-up (12-wk and 1-y postpar-
tum). This work is supported by another
study by Hahn-Holbrook et al22 which
found greater increases between 29 weeks
and 37 weeks’ gestation in CRH associated
with later PPD symptoms. Despite these 3
studies highlighting CRH as a predictor of
PPD, work by Glynn and Sandman did
not find CRH to be predictive of PPD in a
similar longitudinal sampling of CRH and
mood across pregnancy and up to 6-month
postpartum.23 Overall, CRH may be
a viable biomarker in the future if more
work is conducted to replicate previous
findings using consensus sampling and
measurement protocols.
sample of 307 pregnant women, Yim et al15 
took blood samples at multiple timepoints 
during gestation and a 9-week postpartum
visit. Upon analyses, β-endorphin levels and 
depression status [using edinburgh postnatal 
depression scale (EPDS) score > 10] at 25 
weeks’ gestation predicted PPD status at the 
9-week postpartum visit. Although other 
antepartum timepoints were assessed, only 
the 25-week assessment was significantly 
predictive of future PPD. Compared with 
other biomarkers in this review, this predic-
tive model only requires a single assessment 
and biological sampling to determine case 
status. However, this finding needs to be 
replicated before implementing in clinical 
practice.
Cortisol
The stress hormone cortisol has been widely 
investigated in psychiatric disorder etiology. 
However, longitudinal studies into the role 
of cortisol with PPD onset have yielded 
largely null results. The single study which 
identified predictive value for cortisol also 
examined the role of several inflammatory 
molecules across 7 timepoints.16 The final 
predictive model requires measures of sali-
vary cortisol and plasma-derived inflamma-
tory markers [interleukin (IL)-8 and IL-10] 
at day 14 postpartum to predict PPD 
through 6-month postpartum. These con-
stitute multiple measures from multiple 
tissues, making the clinical implementation 
challenging, but not impossible. However, 1 
limitation of this study is that it will miss any 
PPD onset that occurs within the first 2 
weeks following childbirth. However, this 
interesting study should be compared with 
the other studies17,18 that did not find 
predictive power in cortisol measurements. 
The lack of other positive findings may be a 
result of differing sample sources, diagnostic 
definitions, and collection times.
Corticotropin-releasing Hormone (CRH) 
Similar to cortisol, CRH is investigated in 
psychiatric disorders for its role in HPA-
axis function and stress response. 
During
Oxytocin
The oxytocin signaling network has been
of great interest to perinatal mental health
researchers for many years due to its role
in bonding and mother-infant interac-
tions. Recent work has begun to identify
the trajectories of oxytocin through preg-
nancy and into the postpartum period,
with a focus on how PPD onset poten-
tially alters these trajectories. The first of
these studies came in 2011 when Skrundz
et al24 measured plasma oxytocin levels
during the third trimester of pregnancy in
74 women. Depression status was as-
sessed at baseline and 2-week postpartum.
They found that plasma oxytocin levels
during the third trimester can predict
PPD symptoms at 2-week postpartum.
Moreover, their findings showed that
those with EPDS scores ≥ 10 at baseline
were characterized by lower oxytocin
concentrations. These initial findings
were followed-up in 2 studies in 2016.
First, Jobst et al25 evaluated 100 women
for depression symptoms and plasma oxy-
tocin levels at 2 timepoints during preg-
nancy (35 and 38 wk) and 3 times
postpartum (2 d, 7 wk, 6 mo). With multi-
ple timepoints they showed plasma oxy-
tocin levels increased from week 35 of
pregnancy to 6-month postpartum in all
women. However, those women who
developed PPD showed a characteristic
drop in oxytocin levels from week 38 of
gestation to 2 days after delivery, where
those without PPD continuously increase.
This finding supports work by Skrundz
and colleagues proposing that oxytocin
may be a predictor of PPD in the imme-
diate postpartum period (within 2 weeks).
This window may be critical for predic-
tion because when measuring PPD status
at 6-week postpartum, Massey et al26
were unable to find differences in third
trimester oxytocin levels alone that pre-
dict PPD status. However, using past
history of MDD in their prediction model
shows an interaction with oxytocin levels
to significantly predict PPD symptom
severity. Briefly, they found that higher
levels of oxytocin predicted PPD severity
in women with a history of MDD, but not
in women without such history. Overall,
these 3 studies show that the transition
from gestation to postpartum may be a
critical window for oxytocin prediction of
PPD. In addition, oxytocin trajectory
may be altered by previous MDD history,
which should be accounted for in future
studies evaluating the predictive ability of
serum oxytocin as a biomarker for PPD.
Thyroid Function
During pregnancy several thyroid hor-
mone levels are altered and have been
investigated in relation to perinatal mood
previously.27 Tests that measure various
aspects of thyroid function are readily
available and widely used, specifically
measuring thyroid-stimulating hormone
(TSH), thyroxine (T4), and triiodothyro-
nine (T3). In addition, thyroid peroxidase
(TPO) and thyroid-binding globulin are
other indicators of thyroid function.
However, when examining the role of
thyroid hormones in predicting PPD,
timing is key given thyroid function is
reacting to the constant changes in other
hormones across pregnancy. Albacar
et al28 performed some of the first inves-
tigations into whether thyroid function
can prospectively predict PPD. In a large
cohort (n= 1053), they were not able to
identify any indications that thyroid func-
tion at 2 days after birth could predict
future depression at 8- or 32-week post-
partum. To illustrate the issue of timing,
Sylven et al29 found that TSH levels at
childbirth over the clinical threshold of
4.0 mU/L was associated with increased
risk for PPD (EPDS≥ 12) at 6-month
postpartum [odds ratio (OR), 11.30;
95% confidence interval (CI), 1.93-
66.11). This work by Sylven and col-
leagues examined 227 women, of which
26 (11.5%) developed PPD and 21 had
TSH over the clinical threshold. Although
this is an encouraging finding, it is a small
(AUC=0.86; 95% CI, 0.80-0.92) and 83%
(AUC=0.83; 95% CI, 0.78-0.89), respec-
tively in their study of 296 women. However,
several other studies with larger sample sizes
have reported lack of evidence supporting
inflammatorymarkers as PPDbiomarkers.34
These studies reporting null findings used a
wide range of sample sizes and racial/ethnic
diversity, as well as looking across several
types of inflammatory markers. In 1 study of
note, their molecular predictor did not per-
form better than using previous MDD
diagnoses as a predictor.34 This illustrates
that while associations may be significant,
the ability of inflammatory markers to pre-
dict PPD require much more investigation.
PSYCHIATRIC HISTORY
Perhaps the current greatest predictor of
PPD is the assessment of psychiatric dis-
orders both before and during pregnancy.
The literature has many examples that
illustrate this using both retrospective and
prospective measures. Practically, this
abundance of information can be distilled
into 1 take-home message: it is imperative
to screen patients for psychiatric history to
better evaluate PPD risk.
The literature strongly shows that var-
ious lifetime histories of MDD,5,25,35,36
anxiety,5 PPD,35,37 PMS/PMDD,37 other
mood disorders,38 personality disorders, or
any psychiatric disorders37,39–41 all signifi-
cantly predict increase risk for PPD onset.
Moreover, there is a wealth of literature
showing that antenatal MDD,25,37,42–44
anxiety,5 or other psychiatric disorder40
also significantly increase risk for PPD.
Lastly, there is a great amount of power in
self-reported family history of MDD,45
family history of bipolar disorder, and
any psychiatric illness.39,46 Unlike many
other predictors of PPD outlined in this
review, assessments of psychiatric history
are validated repeatedly. There is a high
degree of confidence in generating risk
prediction models using these data for
several reasons. First, the literature repre-
sents findings that are globally recognized,
sample that requires replication in larger 
cohorts with more women with PPD. 
Predictors assayed at the time of child-
birth are less practical than those drawn 
earlier in pregnancy, when there is ample 
opportunity for prevention and interven-
tion. Groer and Vaughan30 found that 
TPO-positive women measured between 
16 and 25 weeks gestation were more 
likely to have PPD symptoms 6 months 
after delivery. In a complimentary study, 
Wesseloo et al31 recently found that 
screening positive for TPO-antibodies at 
10 to 12 weeks gestation was associated 
with a nearly 4-fold increased risk (ad-
justed OR, 3.8; 95% CI, 1.3-11.6) for first-
onset depression at 4-month postpartum. 
Taken together, this work suggests that 
recognizing the presence of thyroid-
related immune markers may also predict 
PPD. Increased TSH indicates hypothyr-
oidism, whereas TPO-positive tests sug-
gest autoimmune disorders. If these 
findings are replicated, it could implicate 
thyroid dysfunction as a mechanism con-
tributing to PPD, in addition to providing 
a prospective biomarker for PPD.
Inflammatory Markers
MDD, including PPD, has been associated 
with increased inflammation suggesting a 
shared molecular mechanism for mood dis-
orders and inflammation processes. Identify-
ing this mechanism is a relatively difficult 
task given the degree of cell specificity and 
number of markers that indicate immune 
activation. Two studies suggest that inflam-
matory markers can be more than just 
associated with PPD and prospectively pre-
dict  PPD. First, Krause et al32 found that 
regulatory T cells were increased 34 to 38 
weeks prenatally in mothers who develop 
PPD and are able to significantly predict 
PPD onset. Second, Liu et al33 demonstrate 
that 2 inflammatory markers, IL-6 and high-
sensitivity C-reactive protein, each are inde-
pendently capable of predicting PPD using 
serum at delivery. IL-6 and high-sensitivity 
C-reactive protein had an accuracy of 86%
encompassing women from all genetic and
cultural backgrounds. Second, many of
these studies used multifactorial methods
to look at the effect of psychiatric history
on PPD onset, with most studies finding
psychiatric history as the most significant
predictor associated with prospective case
status. For many nonpsychiatry clinicians,
screening for psychiatric history, either
through diagnostic interview, chart review,
or self-report, is often missed or neglected.
However, this small addition to screening
can improve quality of care for PPDwhich
is currently underdiagnosed and under-
treated.
ADVERSE LIFE EVENTS
If we consider a history of psychiatric
disorders as the best current predictor for
PPD, adverse life events may account for
the next largest source of variation associ-
ated with the disorder. Many studies find a
dose response between adverse life events
and risk for PPD.5 These environmental
risk factors will contribute to an individu-
al’s existing vulnerability to PPD. Many
studies report cumulative measures of ad-
verse life events,5 also referred to stressful
life events.36,47 These reports often use
summary measures to capture cumulative
life events and their effect on PPD risk. In
addition, researchers have attempted to
tease out specific adverse life events that
contribute increased risk.
Evidence has shown in multiple popula-
tions that physical, psychological, or sexual
abuse37,39–41,45,48 significantly increases a
woman’s risk to PPD. There is a single
report that shows lifetime trauma exposure
is not associated with PPD49 identified
among the many positive associations.
Moreover, given the critical role partners
play during the perinatal period, intimate
partner violence (IPV) is especially relevant
to PPD risk.36,43,44,50–52 It should be noted
that 1 study did not identify IPV as a
significant risk factor for PPD,53 though
this could be due to their assessment at
1-month postpartum. Overall, IPV, as well
as more general forms of physical, psycho-
logical, or sexual abuse, has been shown to
increase PPD risk whether it occurs prena-
tally or perinatally.
Perhaps often overlooked adverse life
events in PPD research are issues of immi-
gration and discrimination. These are
important topics to cover because they
represent chronic stressors compared with
singular adverse life events. Albeit small, the
literature shows that both immigration43,54
and discrimination35 increase PPD risk.
Issues of immigration and discrimination
may account for the variation in prevalence
of PPD across racial/ethnic groups, espe-
cially where increased prevalence is ob-
served among immigrants or other groups
experiencing discrimination. Overall, the
current literature shows specific adverse life
events, such as IPV, childhood trauma, or
military deployment, increase risk for PPD.
This increased risk for PPD is also observed
for many other forms of adverse life events
not reported in this review, including di-
vorce, financial hardship, death of a loved
one, natural disasters, and mass conflict.
However, careful assessment of cumulative
life events provides greater power for assess-
ing an individual’s risk for PPD.
Perinatal Risk Factors
During pregnancy and delivery, the moth-
er and baby are carefully monitored for
many medical outcomes. With this comes
a lot of information to make sure devel-
opmental trajectories are met, including
variables that may aid in assessing risk for
PPD. This section reviews risk factors
that may be identified during perinatal
care visits and delivery.
DEMOGRAPHIC INFORMATION
Themost widely studied risk factors for PPD
are derived from demographic information.
In many cases, these data are accessible from
population level data collected a large num-
ber of people at one time, making demo-
graphic data easily accessible to investigate
summed up by the findings of Ertel et al47
which states: “Black andHispanic depressed
mothers were more likely to experience
multiple adversities and less likely to receive
services than white depressed mothers.”
SES
SES refers to a summary measure that
measures a person’s economic and social
position relative to others. Many individual
factors contribute to the measurement of
SES, including education, income, employ-
ment, and insurance status. Overall, SES
has been reported as a significant contrib-
utor to PPD risk.41,48 Specifically, it is low
SES that seems to contribute the greatest
risk to PPD.39,60,62 Indicators of low SES in
the United States are qualifying for the
WIC Program (Special Supplemental Food
Program for Women, Infants, and Chil-
dren) and SNAP (Supplemental Nutrition
Assistance Program). As a potential surro-
gate marker of low SES, women who
reported being on WIC51,63 and SNAP64
have shown increased PPD risk. However,
it is important to note that not every study
finds SES as a risk factor for PPD.42
Educational attainment is one contribu-
ting factor in determining SES. There are
many examples in the literature that show
lower levels of education are associated with
increased risk for PPD.45,47,51,52,55,56,59,62
This may be an effect of lower literacy,
which also has been reported to increase
risk.41 In contrast, there are also findings of
increased levels of education increasing
PPD risk.38 The differences in associations
should also be noted with the negative
findings observed between level of educa-
tion and risk for PPD.50,54,58
One of the main drivers of SES is income.
Low household income increases the odds of
developing PPD,36,47,51,55,56,62 though not all
studies find this association.58 Just as indi-
vidual income is negatively associated with
PPD risk, so is domestic economic
performance.65 Employment status is amore
direct influence on an individual’s income.
Therefore, it makes sense that employment
associations with PPD. Some studies inter-
rogate a wide range of demographic varia-
bles and report no associations with PPD 
risk.42 There are also many demographic 
factors reported in the literature with mixed 
results.
Maternal Age
Much of the literature implicating  age as a  
risk factor for PPD does so in very general 
terms.55 Other studies show maternal age of 
PPD onset appears to have a U-shaped 
curve of increased risk as age increases. 
That is, risk for PPD is higher under the age 
of ~24,38,45,48,51,52,56 decreasing between the 
ages of 24 to 35,57 and increasing again over 
the age of 35.45 These age specific changes 
in PPD risk may reflect periods of stress 
and degrees of social support. However, 
there are also multiple studies that do not 
find such associations between age and 
PPD risk.41,50,54,58
Race
The topic of race and ethnicity in the area of 
biomedical research is a complicated one. 
There are studies that find associations with 
PPD risk and race,59 and those that do 
not.5,50,54,58,60 Discrepancies here may be 
due to the fact that race/ethnicity may be 
proxies for environmental rather than bio-
logical factors. Race is typically associated 
with one’s skin color, whereas ethnicity 
correlates with language. The preferred 
measure to examine the biological related-
ness between individuals is genetic ancestry. 
There has been a single study investigating 
the role of genetic ancestry with PPD risk 
and found no association.5 This study also 
found that self-reported race/ethnicity did 
not correlate well with genetic ancestry. 
Other studies have identified socioeconomic 
status (SES), community of residence, and 
immigrant status as moderating factors for 
discrepancies between PPD risk and race.60 
In addition, differences observed in race 
may be attributable to discrimination61 (see 
the Adverse Life Events section). Although 
these issues of racial disparities are best
status also has been associated with PPD
risk,44,56,62 though not always.50
OBSTETRICAL OUTCOMES
Preterm Birth
Preterm neonates (born before 37 completed
weeks’ gestation) account for 70% of neo-
natal morbidity, 50% of infant hospitaliza-
tion costs, and carry a 40× increased risk of
neonatal death compared with their term
counterparts.66 Surviving neonates also carry
a disproportionate share of lifelong compli-
cations, including cerebral palsy, respiratory
illness, blindness, and deafness.67 Preterm
birth is triggered by multiple mechanisms,
including hormonal mediation, inflamma-
tion and infection, and genetic factors, con-
verging in a final common pathway of
delivery earlier than 37 weeks.68
Despite the multiple underlying etiolo-
gies, there are clear links between stress,
depression, and preterm birth. Tradition-
ally, studies evaluating the association be-
tween depression and preterm birth in
particular have been challenging to inter-
pret due to potential confounding effects of
antidepressant use. A recent systematic re-
view of 14 studies including 25,663 women
found that those with untreated depression
during pregnancy have a significantly
elevated risk for preterm birth (adjusted
OR, 1.56; 95% CI, 1.25-1.94) compared
with women without depression.69 Further,
there was a trend towards an even greater
preterm birth risk in women with severe
depression.69 Another study of 2208
women showed that women with MDD
and posttraumatic stress disorder have a
>4-fold increased risk for preterm birth
(adjusted OR, 4.08; 95% CI, 1.3-13.2); this
risk is greater than—and independent of—
antidepressant use and not a function of
acute mood or anxiety symptoms.70 Cumu-
lative psychosocial stress was also found to
be a significant risk factor for preterm
delivery <37 weeks’ gestation among 3021
women in Canada (OR, 1.73; 95%CI, 1.07-
2.81). Importantly, in this cohort, preterm
birth risk was highest among those with low
levels of social support or optimism.71
Higher general levels of stress72 and higher
perceived racial discrimination73—which
may be linked with depression—have also
been associated with elevated risk for spon-
taneous preterm birth.
Similarly, as expected, preterm birth is
associated with an elevated risk for PPD in
multiple studies, including population-based
studies, with the magnitude of the effect
ranging from OR, 1.35 to 1.74.74–76 One
systematic review found rates of PPD as
high as 40% among women who delivered
preterm.77 However, studies in this area
should be interpreted with caution because
many do not control for depression and
other psychiatric illnesses during pregnancy.
Putative Molecular
Mechanisms for PPD
When we examine the risk factors that
contribute most to risk for PPD, it seems to
strongly support a gene-environment interac-
tion model. Genetic studies show there is a
large heritable component to PPD (~50%).
An individual’s genes are deterministic for
developing PPD, but it provides an inherent
level of risk that is ever present. This level of
risk is only exacerbated by environmental
factors that significantly increase risk: pre-
vious psychiatric history, adverse life events,
decreased SES, and negative obstetrical out-
comes.What these environmental risk factors
have in common is that they increase stress
levels and alter the HPA-axis. This is signifi-
cant because increased levels of stress only
exacerbate underlying genetic levels of risk. In
summary, manifestation of PPD is a result of
inherent genetic risk plus environmental in-
sults reaching a threshold level of risk.
Clinical Implications
Biomarkers for PPD show a lot of prom-
ise but none are ready for clinical use yet.
Work in genetics and epigenetics show a
an individual’s risk for PPD. In addition,
monitoring of any adverse obstetrical
outcomes is critical as this also increases
the odds of developing PPD. Future work
will need to be conducted to formalize this
process and evaluate metrics for efficacy,
though this should not prevent clinicians
from using these methods. Ongoing re-
search will hopefully replicate some of the
biomarker findings and lead to novel
ways of predicting those at risk to prevent
unnecessary suffering for women, their
children and families.
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